Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 1/20 | 0.71 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.46 |
| ▸ | KRAS | P01116 | 4/20 | 0.45 |
| ▸ | EIF4E | P06730 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361534 | 0.85 | DCPS (0.95) | DCPSNT5ETGM2FUT5KRAS | |
| SCHEMBL29689260 | 0.82 | DCPS (0.92) | DCPSNT5ETGM2FUT5KRAS | |
| Lithium Ion SCHEMBL30666140 | 0.76 | NT5E (0.70) | DCPSNT5ETGM2FUT5KRAS | |
| SCHEMBL5172376 | 0.75 | NT5E (0.74) | DCPSNT5ETGM2FUT5KRAS | |
| SCHEMBL1096046 | 0.75 | NT5E (0.73) | DCPSNT5ETGM2FUT5KRAS | |
| SCHEMBL29824509 | 0.74 | DCPS (0.72) | DCPSEIF4E | |
| SCHEMBL29380321 | 0.74 | NT5E (0.68) | DCPSNT5ETGM2FUT5KRAS | |
| Lithium Ion SCHEMBL29529263 | 0.74 | NT5E (0.68) | DCPSNT5ETGM2FUT5KRAS | |
| Water SCHEMBL30173181 | 0.74 | NT5E (0.73) | DCPSNT5ETGM2FUT5KRAS | |
| Gtp SCHEMBL31749625 | 0.73 | NT5E (0.72) | DCPSNT5ETGM2FUT5KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587579-A1 | SYSTEMS AND COMPOSITIONS COMPRISING TRANS-AMPLIFYING RNA VECTORS WITH MIRNA | BioNTech SE (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250134987-A1 | COMPOSITIONS AND METHODS FOR VACCINATION AGAINST PATHOGENIC CORONAVIRUS SPECIES AND VARIANTS | UNITED STATES GOVERNMENT | 2025-05-01 | — | — | US | claimed |
| WO-2025083076-A1 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND THEIR USE IN MEDICINE | BioNTech SE (DE) | 2025-04-24 | — | — | WO | claimed |
| US-12281138-B2 | 5′-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing RNA, expressing proteins in therapy | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2025-04-22 | — | — | US | claimed |
| US-20250122546-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2025-04-17 | — | — | US | claimed |
| CN-118414429-A | RNA constructs and uses thereof | 生物技术欧洲股份公司 | 2024-07-30 | — | — | CN | claimed |
| WO-2024056856-A1 | SYSTEMS AND COMPOSITIONS COMPRISING TRANS-AMPLIFYING RNA VECTORS WITH MIRNA | BioNTech SE (DE) | 2024-03-21 | — | — | WO | claimed |
| US-20260144861-A1 | COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION | BioNTech SE (DE) | 2026-05-28 | — | — | US | disclosed |
| EP-4746919-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF CYTOKINES TO IMMUNE CELLS | BioNTech SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746901-A1 | COMPOSITIONS FOR DELIVERY OF PLASMODIUM ANTIGENS AND RELATED METHODS | BioNTech SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748450-A2 | TREATMENT INVOLVING THERAPEUTIC ANTIBODY AND INTERLEUKIN-2 (IL2) | BioNTech SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746902-A2 | COMPOSITIONS FOR DELIVERY OF PLASMODIUM ANTIGENS AND RELATED METHODS | BioNTech SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107080-A1 | RNA POLYMERASE VARIANTS | CODEXIS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20220122690-A1 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | GENENTECH, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3972632-A1 | THERAPEUTIC RNA FOR OVARIAN CANCER | BioNTech SE (DE) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022058298-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022055867-A2 | SYSTEMS AND METHODS FOR PRODUCING PHARMACEUTICAL COMPOSITIONS USING PERISTALTIC PUMPS AND DAMPENERS | GENENTECH, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3964584-A1 | TRANS-REPLICATING RNA | BioNTech SE (DE) | 2022-03-09 | — | — | EP | disclosed |
| WO-2021156258-A9 | TREATMENT INVOLVING ANTIGEN VACCINATION AND BINDING AGENTS BINDING TO PD-L1 AND CD137 | BioNTech SE (DE) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022029011-A1 | BINDING AGENTS FOR CORONAVIRUS S PROTEIN | BioNTech SE (DE) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144861-A1 | COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION | CD4, LGALS3BP, SARNP | DCPS 1328/4885NT5E 3202/4885TGM2 1440/4885 |
| US-20220122690-A1 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | MICA, HLA-A, HLA-C | DCPS 4475/4885NT5E 3345/4885TGM2 2154/4885 |
| US-12281138-B2 | 5′-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing RNA, expressing proteins in therapy | RNMT, RNGTT, NSUN3 | DCPS 366/4885NT5E 144/4885TGM2 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.